CNTA Form 144: Proposed 12k-share insider sale valued at $168,218
Rhea-AI Filing Summary
Centessa Pharmaceuticals plc (NASDAQ: CNTA) has submitted a Form 144 notifying the SEC of a proposed sale of 12,000 common shares by an insider through UBS Financial Services on 24 June 2025. The estimated aggregate market value is $168,218.40, implying a per-share price of roughly $14.02. The filing states that 133,618,774 shares are outstanding, meaning the planned sale represents less than 0.01 % of total shares. The seller acquired the shares the same day via a cash-settled stock-option exercise.
The insider previously sold a combined 6,000 shares over the past three months for total proceeds of $84,012.01. No additional operational or financial data were disclosed, and the signatory affirms awareness of no undisclosed material adverse information. Given the modest size relative to the float and the routine nature of Form 144 notices, the event is unlikely to materially affect Centessa’s fundamentals or valuation.
Positive
- None.
Negative
- None.
Insights
TL;DR: Minor insider sale; negligible ownership impact; neutral market effect.
The Form 144 reveals an insider’s intent to sell 12,000 CNTA shares, equal to roughly 0.009 % of the company’s outstanding equity. Past 90-day sales totaled another 6,000 shares, suggesting a gradual, modest liquidation pattern rather than aggressive dumping. Because the shares were obtained via option exercise on the same day, the transaction appears to be routine diversification or tax-related liquidity. No 10b5-1 plan date was disclosed, but the attestation of no undisclosed adverse information mitigates governance concerns. Overall, the filing is informational with neutral to immaterial financial impact for investors.